Company Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.
The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies.
It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.
The company was founded in 2010 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Nov 16, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Dr. Paula Ragan Ph.D. |
Contact Details
Address: 61 North Beacon Street Boston, Massachusetts United States | |
| Website | https://www.x4pharma.com |
Stock Details
| Ticker Symbol | XFOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501697 |
| CUSIP Number | 98420X103 |
| ISIN Number | US98420X1037 |
| Employer ID | 27-3181608 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paula Ragan Ph.D. | Chief Executive Officer, President & Director |
| Adam S. Mostafa | Chief Financial Officer, Treasurer & Corporate Secretary |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Keith T. Flaherty M.D. | Founder & Member of Corporate Advisory Board |
| Dr. Renato T. Skerlj Ph.D. | Founder |
| Dr. Richard Peters M.D., Ph.D. | Founder |
| Dr. Robert David Arbeit | Senior Vice President of Clinical Development and Translational Research |
| Mark Baldry M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 4 | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 16, 2024 | 4 | Filing |
| Oct 08, 2024 | 4 | Filing |